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Abstract Background Previous studies have suggest­
ed that hyperhomocysteinemia may be a risk factor for 
venous thrombosis. To assess the risk of venous throm­
bosis associated with hyperhomocysteinemia, we stud­
ied plasma homocysteine levels in patients with a first 
episode of deep-vein thrombosis and in normal control
subjects.
Methods. We measured plasma homocysteine levels 
in 269 patients with a first, objectively diagnosed epi­
sode of deep-vein thrombosis and in 269 healthy con­
trols matched to the patients according to age and sex. 
Hyperhomocysteinemia was defined as a plasma ho­
mocysteine level above the 95th percentile in the control 
group (18.5 /xmol per liter).
Results. Of the 269 patients, 28 (10 percent) had plas­
ma homocysteine levels above the 95th percentile for the 
controls, as compared with 13 of the controls (matched 
odds ratio, 2.5; 95 percent confidence interval, 1.2 to 5.2). 
The association between elevated homocysteine levels 
and venous thrombosis was stronger among women than 
among men and increased with age. The exclusion of 
subjects with other established risk factors for thrombosis 
(e.g., a deficiency of protein C, protein S, or antithrombin; 
resistance to activated protein C; pregnancy or recent 
childbirth; or oral-contraceptive use) did not materially af­
fect the risk estimates.
Conclusions. High plasma homocysteine levels are a 
risk factor for deep-vein thrombosis in the general popu­
lation. (N Engl J Med 1996;334:759-62.)
©1996, Massachusetts Medical Society.
MILD hyperhomocysteinemia is an established risk factor for atherosclerosis and vascular disease.1,2 
In classic homocystinuria, half the vascular complica­
tions are of'venous origin,3 but until recently it has been 
unclear whether mild hyperhomocysteinemia is also a 
risk factor for venous thrombosis.2,1,3 In a case-control 
study. Falcon et al. found that hyperhomocysteinemia 
was a risk factor for thrombosis in people younger than 
40 years of age. They reported that the difference in 
homocystcine levels between case patients and control 
subjects was particularly evident after methionine load­
ing (since methionine is a precursor of homocysteine). 
Recently, we found hyperhomocysteinemia to be a risk 
factor for recurrent venous thrombosis in patients be­
tween 20 and 70 years of age, as compared with controls 
from the general population.7 Although the results of 
these studies support the hypothesis that mild hyperho­
mocysteinemia is a risk factor fur venous thrombosis, 
the studies were not designed to estimate the risk in the 
general population.
We measured homocysteine concentrations in patients 
and matched control subjects participating in the Leiden 
Thrombophilia Study.”'11 This is a population-based 
case-control study designed to measure the effect of sev­
eral acquired and genetic risk factors for thrombosis in 
the general population. Because of the data available 
on the study subjects, we were able to investigate wheth­
er the effect of hyperhomocysteinemia was independent 
of other well-established risk factors for thrombosis, 
such as a deficiency of protein G, protein S, or anti- 
thrombin; use of oral contraceptives; and pregnancy or
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recent childbirth. Recently, resistance to activated pro­
tein G caused by a single point mutation in the factor 
V gene (factor V Leiden) has been reported to be the 
most common hereditary cause of venous thrombosis.1" 
Since hyperhomocysteinemia also appears to be com­
mon, w7e examined the risk of thrombosis in persons with 
both abnormalities.
M e t h o d s
T he  methods by which blood samples were obtained and interview 
data  were collected have been described elsewhere .*'11 The study p ro ­
tocol was approved by the local ethics committee, and all participants 
gave their informed consent. Briefly, consecutive patients younger 
than 70 years o f age who had a first episode of deep-vein thrombosis, 
objectively confirmed (by impedance plethysmography, Doppler ul­
trasonography, compression ultrasonography, or contrast venogra­
phy), between 19B8 and 1993 and who had no known cancer were se­
lected from the files of three anticoagulation clinics in the Netherlands 
(in Leiden, Amsterdam, and Rotterdam). These clinics monitor the 
anticoagulant treatm ent of virtually all patients in well-defined geo­
graphic areas. Each patient was asked to find his or her own healthy 
control subject of the same sex and age (within five years) by asking 
neighbors or friends. We restricted the present analysis to case pa­
tients and controls who were seen at the Leiden Anticoagulation Clin­
ic and whose blood samples were processed and frozen on site with 
minimal delay. (Blood samples from participants in Am sterdam  and 
Rotterdam  were also processed in Leiden, which caused delays of sev­
eral hours, and homocysteine m easurem ents were therefore le.ss accu­
rate than  those measured in samples from subjects in Leiden.11)
The total homocvst.cine concentration was measured in ciliated
d
plasma by automated high-performance liquid chromatography with 
reverse-phase separation and fluorescent detection (with a Gilson 232- 
401 sample processor, Spectra-Physics 8800 solvcnt-delivery system, 
and Spectra-Physics LC 304 fluorometer). We used the method de­
scribed by Fiskerstrand et al.l:! with some modifications.1'1 If not other­
wise stated, hyperhomocysteinemia was defined as a homocysteine lev­
el above the 95th percentile in the control group (18.5/xmol per liter).
We calculated matched odds ratios as estimates of the relative risk 
of thrombosis for homocysteine values above a given point, with the 
matching factor taken into account. The univariate matched odds ra­
tio is the ratio of the num ber of pairs o f case patients and controls in 
which the homocysteine value for the ease patient was above the spec­
ified level and the value for the control was below that level to the 
number of pairs in which the homocysteine value for the control was 
above the specified level and the value for the case patient w^as below 
that level. The 95 percent confidence intervals were calculated from
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a conditional logistic-regression algorithm by the maximum-likeli- 
hood method, with Egret soi l ware. We also investigated a possible 
dose-response  relation by calculating odds ratios for several ranges of 
homocysteine concentrations in a conditional logistic model. In addi­
tion, we calculated odds ratios for men and women separately and for 
several age groups in order to study possible differences in risk among 
these subgroups.
We further explored the differences in risk between men and wom­
en by taking risk factors specific to women into account —  specifical­
ly, the use of oral contraceptives, pregnancy, and recent childbirth. 
We analyzed the risk o f  thrombosis am ong  women less than 50 years 
old, both with and without the inclusion of women with these risk lac- 
tors, by calculating unmatched odds ratios. The use of unmatched 
odds ratios was necessary because in the restricted groups many 
matched pairs would not have been complete. Since the matched and
unmatched odds ratios did not differ substantiallv in anv oi our anal-
t  *
yses, we considered this approach justified.
We also assessed w hether the increased risk associated with hyper- 
homocysteinemia in both sexes was confounded by other risk factors, 
such as a deficiency of protein C, protein S, or antithrombin. We re­
peated the analysis after excluding subjects with abnormally low lev­
els of these proteins (measured, as previously reported, with a single 
lest“) and estimated the risk associated with hyperhomocysteinemia 
in persons with normal protein G, protein S, and antithrombin levels.
Finally, we looked at the possibility o f  an interaction between hy­
perhomocysteinemia and heterozygosity (carrier status) for factor V 
Leiden, a rather common dr ice? that causes resistance to activated 
protein G. We analyzed this interaction by calculating univariate odds 
ratios for thrombosis in persons with both or either o f  these risk fac­
tors, as compared with persons with neither risk factor.
R e s u l t s
The ratio of male to female subjects among both the 
case patients and the controls was 1:1.3, and the mean 
age was 44 years (range, 16 to 70 For the case patients 
and 16 to 71 For the controls); both these variables were 
used in matching the case patients and the controls.
The median plasma homocysteine level in the pa­
tients was 12.9 /xmol per liter (range, 4.8 to 60.2), and 
that in the controls was 12.3 /¿mol per liter (range, 6.4 
to 37.5). The homocysteine concentrations oF individual 
case patients and controls are shown in Figure 1.
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Figure 1. Plasma Homocysteine Levels in 269 Patients with
Deep-Vein Thrombosis and 269 Controls.
Values shown have been rounded.
The 95th percentile oF the homocysteine levels in the 
control group was 18.5 fimol per liter. OF the 269 pa­
tients, 28 (10 percent) exceeded this cutoFF, as com­
pared with 13 (5 percent, by definition) in the control 
group. The matched odds ratio for deep-vein thrombo­
sis in .subjects with a homocysteine concentration above 
the 95th percentile, as compared with those whose ho­
mocysteine levels were at or below that value, was 2.5
(95 percent confidence interval, 1.2 to 5.2). When the 
cutoff was set at the 90th pcrcentile, the matched odds 
ratio was L9 (95 percent confidence interval, 1.1 to 3,3); 
it was 4.0 (95 percent confidence interval, 1.4 to 12.0) 
when the cutoff was the 97.5th percentile (Table 1).
In order to evaluate the possibility oF a close-response 
relation, we stratified the patients and controls accord­
ing to their homocysteine concentrations and calculated 
odds ratios for thrombosis in the patients at the higher 
levels as compared with those at the lowest level, As 
Figure 2 shows, the risk of thrombosis did not increase 
among subjects with homocysteine levels up to 18 /¿mol 
per liter; the risk was greatly increased above 22 /xmol 
per liter, however, indicating a threshold effect rather 
than a continuous dose-response relation.
Odds ratios for several age groups and for men and 
women separately are shown in Table 2. For both sexes, 
there was a sharp increase in the risk of thrombosis as­
sociated with hyperhomocysteinemia at increasing ag­
es. The overall odds ratio for thrombosis associated with 
hyperhomocysteinemia in women was 7.0 (95 percent 
confidence interval, 1.6 to 30.8), and in men it was 1.4 
(95 percent confidence interval, 0.6 to 3.4), with the 
cutoff set at the 95th percentile of the homocysteine 
levels in the control group (P = 0.067 for the compari­
son between the sexes). When we calculated the 95th 
percentile of the distribution of homocysteine levels for 
men and women separately, we Found a 95th percentile 
oF 17.1 jamoi per liter among women and 20.0 /xmol per 
liter among men in the control group. Using these cut- 
oFFs For hyperhomocysteinemia, wc found an odds ratio 
for thrombosis of 3.8 (95 percent confidence interval, 
1.4 to 10.2) for women and 1.8 (95 percent confidence 
interval, 0,6 to 5.4) for men.
The higher rate of hyperhomocysteinemia in wom­
en than in men was present at all ages, making it un­
likely that the difference was due to risk factors spe­
cific to women, such as the use of oral contraceptives, 
recent childbirth, or pregnancy. Indeed, when we ex­
cluded women with these risk factors, the unmatched 
odds ratio for thrombosis that was associated with hy­
perhomocysteinemia (with the 95th percentile for both 
sexes — 18.5 /¿mol per liter — as the cutoff for hyper- 
homocysteinemia) among women under the age of 50 
was 11.3 (95 percent confidence interval, 2.7 to 46.0), 
whereas it was 2.8 (95 percent confidence interval, 0.9 
to 8.7) for all women, both those with and those with­
out these risk factors, under the age of 50.
Of the 269 patients, 15 had protein G deficiency, 7 had 
protein S deficiency, and 10 had antithrombin deficien­
cy. In the control group, Four had protein C deficiency,
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Table 1. Pairwise Distribution of Plasma Ho­
mocysteine Values in 269 Case Patients and 
Their Matched Controls, According to Vari­
ous Definitions of Hyperhomoeysteinemia.*
C’njoi i-: 90m Pi:hc i:nrn.ti (16.6 ¡ imol per liter)
CASI-. I’A'I Il:N 1'S CONTROLS
Above cutoff Below cutoff
Above eutolï  
Below cutoff
6 pairs 38 pairs
20 pairs 205 pairs
Matched odds ratio for thrombosis,
1.9 (95% Cl, 1.1-3.3)
C d t o i k  1>5th  P l r c h n t u . I :  (18 .5  pma\ per  liter)
CAS I: [‘ATILNTS CONTROLS
Above cutoff Below cutoff
Above cutoff 3 pairs 25 pairs
Below culoff 10 pairs 231 pairs
Mulched odds ratio for thrombosis, 
2 .5 (9 5 %  Cl, 1.2-5.2)
C i i t o i t : 1)7 .5 i h  PhKCLNrin: (21,1 /xmol pur liter)
C'ASI: PA I ]I:N IS CONTROLS
Above culoff Below cutoff
Above cutoff 2 pairs 16 pairs
Below cutoff 4 pairs 247 pairs
Matched odds ratio lor thrombosis, 
4 .0 (9 5 %  Cl, 1.4-12.0)
,;I:ur each  cutoff point, subjects classiliccl as having hyperliu- 
mocysteinemia were those with plasma homocysteine levels 
above ihe cutoff value, and subjects classilied as not having hyper- 
homocystcinemia were those with levels at or helow the cutoff 
value (“below c u to f f " ). T h e  percentiles used as cutoffs were for 
the distribution o f  homocysteine values in the control group, Odds 
ratios were calculated us the risk of thrombosis in the subjects with 
hypcrhomocysteinemia as com pared  with that in the subjects 
without hypcrhomocyste inemia.  Cl denotes confidence interval.
eight had protein S deficiency, unci eight had antithrom­
bin deficiency. Alter excluding these subjects, we found 
a matched odds ratio for deep-vein thrombosis of 2.6 (95 
percent confidence interval, 1.2 to 5.9), as compared 
with 2.5 (95 percent confidence interval, 1.2 to 5.2) when 
those subjects were included; this result shows that the 
cffcct of homocysteine is largely independent of these 
deficiencies in clotting-factor inhibitors.
With respect to the combination of factor V Leiden 
and hyperhomoeysteinemia, we calculated odds ratios for 
thrombosis in subjects with both risk factors or either one 
in relation to subjects with neither. A total of 47 of the pa­
tients carried I he factor V Leiden mutation, ¿is compared 
with 7 of the controls. The small number with both de­
fects made the results statistically unstable and some­
what sensitive to the cutoff chosen for elevated homocys­
teine levels. When the 90th percentile was used as the 
cutoff, the odds ratio for thrombosis associated with the 
presence of'both risk factors (factor V Leiden and hyper- 
homocysteinemia) was (95 percent confidence inter­
val, 0.7 to 16.9); the odds ratios lor thrombosis associated 
with factor V Leiden alone and hypcrhomocysteinemia 
alone, calculated separately, were 9.5 and 2.2, respective­
ly. With the 95th percen tile  used as the cutoff, the odds 
ratio for the combination of risk (actors was 2.0 (95 per­
cent confidence interval, 0.1 to 10.9), whereas the odds 
ratios for each risk factor separately remained virtually
unchanged. The statistical uncertainty of results based 
on these data is reflected in the wide confidence inter­
vals, which do not exclude a relative risk as high as 16.9.
D is c u s s io n
Our study show's that hyperhomoeysteinemia is a risk 
factor for deep-vein thrombosis in the general popula­
tion. Moreover, our results suggest that the association 
between mild hyperhomoeysteinemia and venous throm­
bosis is similar in degree to that reported for hyper homo­
cysteinemia and arterial vascular disease,b,lb An unex­
pected finding was the substantial increase in the risk of 
thrombosis at the highest plasma homocysteine levels. 
Our data suggest that there may be a threshold level 
above which homocysteine has a thrombogenic effect.
Falcon et al. reported that hyperhomoeysteinemia was 
a risk factor for juvenile thrombosis.6 Our data imply 
that hyperhomoeysteinemia is a risk factor for thrombo­
sis in adult subjects as well, since w;e found an increasing 
odds ratio with increasing age.
When we analyzed men and women separately, we 
found a difference in the risk of’ thrombosis associated 
wfith hyperhomoeysteinemia. Even when we used differ­
ent cutoff points for hyperhomoeysteinemia in men and 
women by calculating the 95th percentiles of their ho­
mocysteine distributions in the control group separate­
ly, we found that the odds ratio was roughly twice as 
high for women as for men. This .suggests that women 
may be more susceptible to the pathologic effects of el­
evated homocysteine levels, even though their homocys­
teine levels are in general lower than those of men.1 This 
effect cannot be explained by risk factors specific to 
women (such as pregnancy, recent childbirth, and oral- 
contraceptive use); an effect of these risk factors was 
unlikely in any case because the difference between 
men and women who did not have such risk factors was 
even more pronounced.
Hyperhomoeysteinemia remained a risk factor for
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Figure 2. Odds Ratio for Thrombosis According to Plasma Ho­
mocysteine Level.
The reference category was the subjects with plasma homocys­
teine values of <12 /¿mol per liter.
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Table 2. Odds Ratios for Thrombosis Associated 
with Hyperhomocysteinemia, According to Age
and Sex.:,;
Ata- (yr) Min NVomln Both Si:xt;s
mids raiio {95f/< Cl)
< 3 0 0.5 (0.1-5.5) 1.0(0.1-16.0) 0.7 (0.1-4.0)
3 0 -5 0 1.3 (0.3-4.6) 7.0 (0.9-56.9) 2.4 (0.8-6.8)
2=50 2.5 (0.5-12.9) oof 5.5 (1.2-24.8)
All ages 1.4 (0.6-3.4) 7 .0(1 .6-30 .8) 2.5 {1.2-5,2)
*Odds ratios were calculated as (he risk o f  deep-vein  thrombosis  in sub ­
jec ts  with hyperhomocysteinemia (delined as a homocysteine level above 
the 95th percentile in the control group [18.5 /¿moi pe r  liter}) as com pared  
with the risk in those without hyperhomocysteinemia. Cl denotes conli- 
dence  interval.
i T h e  odds ratio was 12.0 (95 percent confidence interval, l.fi to 92.3) 
when the cutoff used was the 90tlt percentile in the control group.
deep-vein thrombosis after we excluded subjects with 
other well-established risk factors; that is, the associa­
tion with thrombosis was not explained by the presence 
of other hereditary risk factors for thrombosis, such as 
a deficiency of protein C, protein S, or antithrombin. The 
same was true of the most common hereditary risk fac­
tor for deep venous thrombosis, resistance to activated 
protein C, since hyperhomocysteinemia also increased 
the risk of thrombosis in those without this abnormal­
ity. We investigated a possible interaction between re­
sistance to activated protein C (factor V Leiden) and hy­
perhomocysteinemia. Although we found that the risk 
of thrombosis may be higher in carriers of the mutation 
who have hyperhomocysteinemia than in noncarriers 
with hyperhomocysteinemia, the combined effect in our 
subjects seemed smaller than for factor V Leiden alone. 
Because of the small numbers involved, the only rea­
sonable conclusion is that the two factors do not poten­
tiate each other.
Many hypotheses have been proposed to explain how 
hyperhomocysteinemia may lead to venous thrombosis 
and atherosclerosis. One hypothesis is that homocys- 
tcinc has a toxic effect on the vascular endothelium and 
on the clotting cascade,1,2 Several in vitro studies seem 
to support this view.17,18 However, virtually all these stud­
ies used amounts of homocysteine that produced high- 
er-than-physiologie concentrations. Alternatively, hy­
perhomocysteinemia may reflect abnormal methionine 
metabolism that affects the methylation of DNA and 
cell membranes.19
Elevated homocysteine levels may result from low lev­
els of folic acid, vitamin B,-, or vitamin B)2. Moreover, sev­
eral genetic alterations in enzymes involved in homocys­
teine metabolism have been described.20'22 It remains 
unclear whether hyperhomocysteinemia of different caus­
es entails the same risk of thrombosis. Nevertheless, it is 
well known that vitamin supplementation lowers ho­
mocysteine concentrations in almost all subjects with hy­
perhomocysteinemia, regardless of the underlying cause.
We conclude that mild hyperhomocysteinemia is a 
risk factor for deep-vein thrombosis in the general pop­
ulation. The next question to be answered is whether 
homocysteine-lowering therapy — folic acid, vitamin
Bfi, o r  vitamin Bl2 — contributes to the prevention of re­
current venous thrombosis.2:i'2f)
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